The U.S. Food and Drug Administration has released an interim final rule and draft guidance documents regarding the manufacturing standards of infant formula. Only 75 percent of infants in the U.S. start out being breastfed and by age three months, two-thirds rely on infant formula for some portion of their nutrition. The rule is meant to ensure that formulas for infants without unusual medical or dietary problems are safe and support healthy growth. The draft guidance documents issued alongside the interim final rule address how manufacturers can demonstrate that their products meet the quality factor requirements of the interim final rule and information about manufacturing formulas made for infants with unusual medical or dietary problems “Many families rely on infant formula as either the sole source of nutrition or an integral part of an infant’s diet through 12 months of age,” said Michael Taylor, the FDA’s deputy commissioner for foods and veterinary medicine. “The FDA sets high quality standards for infant formulas because nutritional deficiencies during this critical time of development can have a significant impact on a child’s long-term health and well-being.” The interim final rule amends the FDA’s quality control procedures, notification, and record and reporting requirements for manufacturers of infant formulas. It also establishes current good manufacturing practices and requires testing for Cronobacter and Salmonella contamination. FDA says that companies currently manufacturing infant formula in the U.S. already voluntarily conduct many of the current good manufacturing practices and quality control procedures included in the rule. The agency will be accepting comments from the public on issues or information not previously considered in the interim final rule.
The News Desk team at Food Safety News covers breaking developments, regulatory updates, recalls, and key topics shaping food safety today. These articles are produced collaboratively by our editorial staff.
A leading academic has warned that any plans for UK regulators to help industry grow could end up repeating past mistakes and impacting public health.
As part of modernization plans,
The FDA has issued final guidance for manufacturers of infant formula and laboratories conducting testing on infant formula.
The guidance was developed to help manufacturers and laboratories in the design,
As part of its enforcement activities, the Food and Drug Administration sends warning letters to entities under its jurisdiction. Some letters are not posted for public view until weeks or
The a2 Milk Company (“a2MC”) has recalled three specific batches of its imported a2 Platinum Premium USA label infant formula 0-12 months because of the presence of cereulide. The product
JXK Enterprises Inc. is recalling Boner Bears Chocolate, Lot #BB21125, after being notified that FDA laboratory analysis confirmed the presence of sildenafil, an active ingredient in the FDA-approved prescription drug
Total Nutrition Inc. of Deer Park, NY, is recalling TNVitamins Ultra Potent Complete Green Superfood and Doctor’s Pride Complete Green Superfood Ultra Potent Moringa Capsules because they have the
Bazzini LLC, of Allentown, PA, a co-manufacturer utilized by SkinnyDipped, is recalling a limited number of cases of SkinnyDipped Dark Chocolate Coconut Almond Bites, because of the possible presence of
